간암 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 암 유형별, 기기별, 연령별, 요인별, 투여 경로별, 유통 채널별, 지역별 및 경쟁 상황(2021-2031년)

Liver Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type, By Equipment, By Age, By Factors, By Route of Administration, By Distribution channel, By Region & Competition, 2021-2031F

US $ 4,500 ￦ 6,592,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,057,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,720,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 간암 치료제 시장은 2025년 41억 1,000만 달러에서 2031년까지 69억 4,000만 달러로 확대되고, CAGR 9.12%를 기록할 것으로 예측됩니다.

이 시장은 간세포암 및 간내 담관암 치료를 위한 표적 치료제, 면역치료제, 화학요법제를 포함한 약리학적 개입을 포괄하고 있습니다. 성장의 주요 요인은 만성 B형 및 C형 간염의 전 세계 발생률 증가와 대사증후군과 관련된 비알코올성 지방간 질환의 유병률 증가에 기인합니다. 또한, 의료비 증가와 고령화 인구구조는 첨단 임상 솔루션에 대한 견고한 수요를 뒷받침하고 있으며, 일시적인 추세를 넘어 지속적인 성장을 보장하고 있습니다.

시장 개요
예측 기간	2027-2031년
시장 규모 : 2025년	41억 1,000만 달러
시장 규모 : 2031년	69억 4,000만 달러
CAGR : 2026-2031년	9.12%
가장 빠르게 성장하는 부문	표적요법
최대 시장	북미

반면, 혁신적인 생물학적 치료와 병용요법에 따른 막대한 비용은 시장 성장의 큰 장벽으로 작용하고 있으며, 특히 개발도상국 환자들의 접근성을 제한하고 있습니다. 이러한 경제적 문제는 치료적 개입의 유용성을 제한하고 의료 예산에 부담을 주는 진행성 진단의 높은 빈도로 인해 더욱 악화되고 있습니다. 미국암협회에 따르면, 2024년 간암으로 인해 전 세계적으로 70만 명 이상이 사망할 것으로 예상됩니다.

이 통계는 이 질환의 높은 사망률에 대처하기 위해 비용 효율적인 치료법 개발이 시급하다는 점을 강조하고 있습니다.

시장 촉진요인

시장 확대는 기본적으로 만성 B형 및 C형 간염 바이러스 감염의 심각한 부담에 의해 추진되고 있습니다. 이들은 전 세계적으로 간세포암의 주요 원인으로 꼽힙니다. 만성 바이러스성 간염이 간경변증과 악성 종양으로 진행됨에 따라 장기적인 관리와 약리학적 개입에 대한 지속적인 요구가 발생하여 항바이러스 치료와 항종양 치료의 수요를 직접적으로 견인하고 있습니다. 지난 4월 발표된 세계보건기구(WHO)의 '2024 세계 간염 보고서'에 따르면, 2022년 기준 전 세계 만성 B형 간염 환자는 약 2억 5,400만 명, C형 간염 환자는 5,000만 명에 달할 것으로 예상되며, 질병 조절 치료와 경과 관찰이 필요한 방대한 환자층이 존재한다는 사실을 강조하고 있습니다. 되었습니다.

동시에, 이 분야는 새로운 면역요법 및 병용요법의 도입이 가속화되면서 재편되고 있습니다. 이들은 절제 불가능한 질환에 대한 표준 치료제로서 기존의 전신 치료제를 크게 능가하고 있습니다. 제약사들은 생존율 향상을 가져오는 체크포인트 억제제의 상용화를 적극적으로 추진하고 있으며, 선진국 시장에서는 빠르게 보급이 진행되고 있습니다. 예를 들어, 아스트라제네카는 2024년 11월 '2024년 3분기 결산'에서 면역치료제 임핀지의 3분기 단독 매출액이 16억 달러에 달했다고 보고했습니다. 이는 종양학 분야의 수요에 힘입어 전년 동기 대비 31% 증가한 수치입니다. 이러한 생물학적 제제의 이용 급증은 진단율의 지속적인 증가와 일치합니다. 미국암협회(American Cancer Society)의 'Cancer Facts & Figures 2024'에 따르면, 2024년 미국에서 41,630건의 간암 및 간내 담관암이 새롭게 발생할 것으로 예상되며, 이는 이러한 첨단 치료법의 필요성이 매우 높다는 것을 보여줍니다. 필요성이 매우 높다는 것을 뒷받침하고 있습니다.

시장의 과제

생물학적 제제 치료 및 병용요법에 따른 막대한 경제적 부담은 세계 간암 치료제 시장의 주요 제약요인으로 작용하고 있습니다. 높은 의약품 개발 및 제조 비용은 최종사용자에 대한 가격 상승을 초래하고, 특히 의료 보험 상환 제도가 불충분한 개발도상국에서는 환자의 접근성을 제한합니다. 공중보건 예산이나 환자 개개인의 부담 능력을 초과하는 가격이 책정되면 치료법 채택률이 현저하게 둔화됩니다. 이러한 경제적 장벽은 임상 솔루션의 보급을 가로막고, 결과적으로 제조업체의 잠재적 수익원을 감소시켜 시장 확대를 저해합니다.

이러한 문제는 환자 1인당 높은 치료 비용과 질병의 높은 유병률로 인해 더욱 심각해집니다. 시장은 발생률에 따른 높은 수요와 광범위한 치료의 낮은 경제적 타당성이라는 두 가지 모순에 직면해 있습니다. 미국암협회에 따르면, 2024년 미국에서 새로 진단된 간암은 약 41,630건으로 추정됩니다. 이러한 환자 수를 고가의 치료제로 치료하기 위해 필요한 누적 비용은 보험회사나 국가 의료제도에 큰 부담을 주고 있습니다. 그 결과, 지불 기관은 종종 엄격한 상환 기준을 도입하여 대상 시장 규모를 제한하고 전체 산업의 성장 궤도를 저해하고 있습니다.

시장 동향

국소요법과 전신요법의 융합은 치료 환경을 빠르게 변화시키고 있으며, 특히 기존에는 카테터 기반 중재요법만으로 관리되던 중간기 간세포암 환자에서 두드러지게 나타나고 있습니다. 이러한 추세는 색전술 단독요법에 따른 높은 재발률을 낮추기 위해 전신면역요법을 직접 경동맥화학색전술(TACE)과 통합하는 것입니다. 치료 과정의 초기 단계에서 생물학적 제제를 도입함으로써 임상의는 미세 전이 병변을 표적으로 삼고 장기적인 치료 결과를 개선하고자 합니다. The Lancet 1월호에 발표된 'EMERALD-1 시험 결과'에 따르면, 듀발루맙, 베바시주맙, TACE 병용요법은 무진행생존기간 중앙값 15.0개월을 달성해 표준 TACE 프로토콜 대비 통계적으로 유의미한 개선 효과를 보였으며 첨단 치료법의 활용 범위를 효과적으로 확대하였습니다.

동시에 시장에서는 차세대 경구용 티로신 키나아제 억제제(TKI)의 부활과 진화가 진행되고 있으며, 특히 새로운 병용 전략에 대한 새로운 유효성 기준이 확립되고 있습니다. 기존의 전신 치료제와 달리, 이러한 최신 저분자 억제제는 체크포인트 억제제와 병용하여 절제 불가능한 병변에서 기존의 임상적 한계에 도전하는 생존기간 연장 효과를 가져오고 있습니다. 이러한 추세는 키나아제 억제제가 치료의 기초로서 지속적으로 중요하다는 것을 보여줍니다. 2025년 10월 'The ASCO Post'에 따르면, 'CARES-310 임상 최종 분석'에서 티로신 키나아제 억제제 리보세라닙과 캄렐리주맙 병용요법은 중앙값 23.8개월의 전체생존기간을 보였다고 합니다. 이는 해당 적응증에 대한 국제 임상 3상 시험에서 보고된 치료법 중 가장 긴 기간으로, 표적 경구용 약물의 역할이 다시 활성화되고 있음을 입증합니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 간암 치료제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 암 종류별(간세포암, 담관암, 간전이, 간아종, 혈관육종)
  • 치료법별(표적요법, 방사선 치료 및 화학요법, 면역요법, 기타)
  • 장비별(컴퓨터 방사선 촬영, MRI, 초음파 검사, 기타)
  • 연령별(0-18세,18-35세,35-50세, 50세 이상)
  • 요인별(비알코올성 지방간질환, 간경변, 과도한 간 소비, 기타)
  • 투여 경로별(경구, 정맥내, 기타)
  • 유통 경로별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2025)
• 시장 맵

제6장 북미의 간암 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 간암 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 간암 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 간암 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 간암 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 간암 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Bayer AG
• Bristol Myers Squibb
• Merck & Co., Inc.
• Exelixis, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• AstraZeneca PLC

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Liver Cancer Therapeutics Market is projected to expand from USD 4.11 Billion in 2025 to USD 6.94 Billion by 2031, reflecting a CAGR of 9.12%. This market encompasses pharmacological interventions, including targeted therapies, immunotherapies, and chemotherapeutic agents, designed to treat hepatocellular carcinoma and intrahepatic bile duct cancers. Growth is primarily driven by the rising global incidence of chronic Hepatitis B and C infections, along with the increasing prevalence of non-alcoholic fatty liver disease linked to metabolic syndromes. Furthermore, increased healthcare expenditure and an aging population are supporting robust demand for advanced clinical solutions, ensuring growth beyond temporary trends.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 4.11 Billion
Market Size 2031	USD 6.94 Billion
CAGR 2026-2031	9.12%
Fastest Growing Segment	Targeted Therapy
Largest Market	North America

Conversely, the substantial costs associated with innovative biologic treatments and combination regimens present a major obstacle to market growth, restricting patient access particularly in developing economies. This economic challenge is compounded by the high frequency of late-stage diagnoses, which limits the utility of curative interventions and strains healthcare budgets. According to the American Cancer Society, liver cancer caused over 700,000 deaths globally in 2024. This statistic highlights the urgent necessity for cost-effective therapeutic advancements to address the high mortality rates associated with the disease.

Market Driver

The market's expansion is fundamentally propelled by the significant burden of chronic Hepatitis B and C viral infections, which act as the leading causes of hepatocellular carcinoma worldwide. As chronic viral hepatitis progresses to liver cirrhosis and malignancy, it creates a continuous need for long-term management and pharmacological intervention, directly driving the demand for antiviral and antineoplastic treatments. According to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, approximately 254 million people were living with chronic hepatitis B and 50 million with hepatitis C globally in 2022, underscoring the vast population requiring disease-modifying therapies and surveillance.

Simultaneously, the sector is being reshaped by the accelerated adoption of novel immunotherapy and combination regimens, which have largely superseded older systemic agents as the standard of care for unresectable disease. Pharmaceutical developers are actively commercializing checkpoint inhibitors that offer superior survival rates, leading to rapid uptake in developed economies. For instance, AstraZeneca reported in its 'Q3 2024 Results' in November 2024 that the immunotherapy agent Imfinzi generated $1.6 billion in sales in the third quarter alone, a 31% year-over-year increase driven by oncology demand. This surge in biologic utilization coincides with persistent diagnostic rates; the American Cancer Society's 'Cancer Facts & Figures 2024' projected 41,630 new cases of liver and intrahepatic bile duct cancer in the US for the year, reinforcing the critical need for these advanced options.

Market Challenge

The significant financial burden associated with biologic treatments and combination regimens serves as a primary restraint on the global liver cancer therapeutics market. High drug development and manufacturing expenses result in elevated pricing for end users, which limits patient access, particularly in developing regions with inadequate healthcare reimbursement frameworks. When pharmacological interventions are priced beyond the reach of public health budgets and individual patients, adoption rates slow considerably. This economic barrier prevents the widespread utilization of clinical solutions, thereby reducing potential revenue streams for manufacturers and stalling market expansion.

This challenge is further compounded when the high cost per patient is multiplied by the significant prevalence of the disease. The market faces a dichotomy where demand is robust due to incidence rates, yet the economic feasibility for widespread treatment remains low. According to the American Cancer Society, an estimated 41,630 new cases of liver cancer were diagnosed in the United States in 2024. The cumulative cost required to treat such a volume of patients with premium-priced therapeutics places immense pressure on insurance providers and national health systems. Consequently, payers often implement strict reimbursement criteria, which limits the addressable market size and hampers the overall growth trajectory of the industry.

Market Trends

The Convergence of Locoregional and Systemic Therapies is rapidly transforming the treatment landscape, specifically for patients with intermediate-stage hepatocellular carcinoma who were historically managed with catheter-based interventions alone. This trend involves the integration of systemic immunotherapies directly with transarterial chemoembolization (TACE) to reduce the high rates of disease recurrence associated with embolization monotherapy. By introducing biologic agents earlier in the treatment continuum, clinicians aim to target micrometastatic disease and improve long-term outcomes. According to The Lancet in January 2025, the 'EMERALD-1 study results' showed that the combination of durvalumab, bevacizumab, and TACE achieved a median progression-free survival of 15.0 months, a statistically significant improvement over the standard TACE protocol, effectively expanding the utilization of advanced therapeutics.

Simultaneously, the market is witnessing the resurgence and evolution of Next-Generation Oral Tyrosine Kinase Inhibitors (TKIs), which are establishing new efficacy benchmarks particularly when utilized in novel combination strategies. Unlike legacy systemic agents, these modern small molecule inhibitors are being paired with checkpoint inhibitors to deliver extended survival benefits that challenge historical clinical ceilings in unresectable disease. This trend highlights the continued relevance of kinase inhibitors as a cornerstone of therapy. According to The ASCO Post in October 2025, the 'CARES-310 trial final analysis' reported that the combination of the tyrosine kinase inhibitor rivoceranib and camrelizumab demonstrated a median overall survival of 23.8 months, the longest duration reported for any treatment in a global Phase 3 study for this indication, underscoring the revitalized role of targeted oral agents.

Key Market Players

• Bayer AG
• Bristol Myers Squibb
• Merck & Co., Inc.
• Exelixis, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• AstraZeneca PLC

Report Scope

In this report, the Global Liver Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liver Cancer Therapeutics Market, By Cancer Type

• Hepatocellular Carcinoma
• Cholangiocarcinoma
• Liver Metastasis
• Hepatoblastoma
• Angiosarcoma

Liver Cancer Therapeutics Market, By Therapy

• Targeted Therapy
• Radiation and Chemotherapy Therapy
• Immunotherapy
• Others

Liver Cancer Therapeutics Market, By Equipment

• Computed Radiography
• MRI
• Sonography
• Others

Liver Cancer Therapeutics Market, By Age

• 0-18
• 18-35
• 35-50
• 50+

Liver Cancer Therapeutics Market, By Factors

• Non-Alcoholic Fatty Liver Disease
• Cirrhosis
• Excessive Liver Consumption
• Others

Liver Cancer Therapeutics Market, By Route of Administration

• Oral
• Intra-Venous
• Others

Liver Cancer Therapeutics Market, By Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Liver Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liver Cancer Therapeutics Market.

Available Customizations:

Global Liver Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liver Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastasis, Hepatoblastoma, Angiosarcoma)
  • 5.2.2. By Therapy (Targeted Therapy, Radiation and Chemotherapy Therapy, Immunotherapy, Others)
  • 5.2.3. By Equipment (Computed Radiography, MRI, Sonography, Others)
  • 5.2.4. By Age (0-18, 18-35, 35-50, 50+)
  • 5.2.5. By Factors (Non-Alcoholic Fatty Liver Disease, Cirrhosis, Excessive Liver Consumption, Others)
  • 5.2.6. By Route of Administration (Oral, Intra-Venous, Others)
  • 5.2.7. By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.8. By Region
  • 5.2.9. By Company (2025)
• 5.3. Market Map

6. North America Liver Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapy
  • 6.2.3. By Equipment
  • 6.2.4. By Age
  • 6.2.5. By Factors
  • 6.2.6. By Route of Administration
  • 6.2.7. By Distribution channel
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Liver Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Equipment
      • 6.3.1.2.4. By Age
      • 6.3.1.2.5. By Factors
      • 6.3.1.2.6. By Route of Administration
      • 6.3.1.2.7. By Distribution channel
  • 6.3.2. Canada Liver Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Equipment
      • 6.3.2.2.4. By Age
      • 6.3.2.2.5. By Factors
      • 6.3.2.2.6. By Route of Administration
      • 6.3.2.2.7. By Distribution channel
  • 6.3.3. Mexico Liver Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Equipment
      • 6.3.3.2.4. By Age
      • 6.3.3.2.5. By Factors
      • 6.3.3.2.6. By Route of Administration
      • 6.3.3.2.7. By Distribution channel

7. Europe Liver Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapy
  • 7.2.3. By Equipment
  • 7.2.4. By Age
  • 7.2.5. By Factors
  • 7.2.6. By Route of Administration
  • 7.2.7. By Distribution channel
  • 7.2.8. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Liver Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Equipment
      • 7.3.1.2.4. By Age
      • 7.3.1.2.5. By Factors
      • 7.3.1.2.6. By Route of Administration
      • 7.3.1.2.7. By Distribution channel
  • 7.3.2. France Liver Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Equipment
      • 7.3.2.2.4. By Age
      • 7.3.2.2.5. By Factors
      • 7.3.2.2.6. By Route of Administration
      • 7.3.2.2.7. By Distribution channel
  • 7.3.3. United Kingdom Liver Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Equipment
      • 7.3.3.2.4. By Age
      • 7.3.3.2.5. By Factors
      • 7.3.3.2.6. By Route of Administration
      • 7.3.3.2.7. By Distribution channel
  • 7.3.4. Italy Liver Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Equipment
      • 7.3.4.2.4. By Age
      • 7.3.4.2.5. By Factors
      • 7.3.4.2.6. By Route of Administration
      • 7.3.4.2.7. By Distribution channel
  • 7.3.5. Spain Liver Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Equipment
      • 7.3.5.2.4. By Age
      • 7.3.5.2.5. By Factors
      • 7.3.5.2.6. By Route of Administration
      • 7.3.5.2.7. By Distribution channel

8. Asia Pacific Liver Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapy
  • 8.2.3. By Equipment
  • 8.2.4. By Age
  • 8.2.5. By Factors
  • 8.2.6. By Route of Administration
  • 8.2.7. By Distribution channel
  • 8.2.8. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Liver Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Equipment
      • 8.3.1.2.4. By Age
      • 8.3.1.2.5. By Factors
      • 8.3.1.2.6. By Route of Administration
      • 8.3.1.2.7. By Distribution channel
  • 8.3.2. India Liver Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Equipment
      • 8.3.2.2.4. By Age
      • 8.3.2.2.5. By Factors
      • 8.3.2.2.6. By Route of Administration
      • 8.3.2.2.7. By Distribution channel
  • 8.3.3. Japan Liver Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Equipment
      • 8.3.3.2.4. By Age
      • 8.3.3.2.5. By Factors
      • 8.3.3.2.6. By Route of Administration
      • 8.3.3.2.7. By Distribution channel
  • 8.3.4. South Korea Liver Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Equipment
      • 8.3.4.2.4. By Age
      • 8.3.4.2.5. By Factors
      • 8.3.4.2.6. By Route of Administration
      • 8.3.4.2.7. By Distribution channel
  • 8.3.5. Australia Liver Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Equipment
      • 8.3.5.2.4. By Age
      • 8.3.5.2.5. By Factors
      • 8.3.5.2.6. By Route of Administration
      • 8.3.5.2.7. By Distribution channel

9. Middle East & Africa Liver Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapy
  • 9.2.3. By Equipment
  • 9.2.4. By Age
  • 9.2.5. By Factors
  • 9.2.6. By Route of Administration
  • 9.2.7. By Distribution channel
  • 9.2.8. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Liver Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Equipment
      • 9.3.1.2.4. By Age
      • 9.3.1.2.5. By Factors
      • 9.3.1.2.6. By Route of Administration
      • 9.3.1.2.7. By Distribution channel
  • 9.3.2. UAE Liver Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Equipment
      • 9.3.2.2.4. By Age
      • 9.3.2.2.5. By Factors
      • 9.3.2.2.6. By Route of Administration
      • 9.3.2.2.7. By Distribution channel
  • 9.3.3. South Africa Liver Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Equipment
      • 9.3.3.2.4. By Age
      • 9.3.3.2.5. By Factors
      • 9.3.3.2.6. By Route of Administration
      • 9.3.3.2.7. By Distribution channel

10. South America Liver Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapy
  • 10.2.3. By Equipment
  • 10.2.4. By Age
  • 10.2.5. By Factors
  • 10.2.6. By Route of Administration
  • 10.2.7. By Distribution channel
  • 10.2.8. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Liver Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Equipment
      • 10.3.1.2.4. By Age
      • 10.3.1.2.5. By Factors
      • 10.3.1.2.6. By Route of Administration
      • 10.3.1.2.7. By Distribution channel
  • 10.3.2. Colombia Liver Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Equipment
      • 10.3.2.2.4. By Age
      • 10.3.2.2.5. By Factors
      • 10.3.2.2.6. By Route of Administration
      • 10.3.2.2.7. By Distribution channel
  • 10.3.3. Argentina Liver Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Equipment
      • 10.3.3.2.4. By Age
      • 10.3.3.2.5. By Factors
      • 10.3.3.2.6. By Route of Administration
      • 10.3.3.2.7. By Distribution channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Liver Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol Myers Squibb
• 15.3. Merck & Co., Inc.
• 15.4. Exelixis, Inc.
• 15.5. Eisai Co., Ltd.
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Pfizer Inc.
• 15.8. Eli Lilly and Company
• 15.9. Novartis AG
• 15.10. AstraZeneca PLC

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료